Development and First Validation of a Disease Activity Score for Gout

Area of Science:

• Rheumatology
• Clinical assessment
• Gout management

Background:

• Gout disease activity is characterized by persistent urate deposits causing arthritis and joint damage.
• Current assessment methods may not fully capture the multifaceted nature of gout disease activity.
• Outcome Measures in Rheumatology (OMERACT) core domains provide a framework for evaluating disease activity.

Purpose of the Study:

• To develop and validate a novel composite disease activity score for gout.
• To establish a reliable measure for assessing ongoing disease activity in gout patients.
• To provide a tool for clinical decision-making in gout management.

Main Methods:

• A 3-step approach involving factor analysis, linear discriminant analysis, and linear regression was used.
• Data from 446 patients in the Italian Network for Gout cohort were analyzed.
• Construct and criterion validity were tested, with external validation performed on an independent sample.

Main Results:

• Factor analysis identified five key domains: patient-reported outcomes, joint examination, flares, tophi, and serum uric acid (sUA).
• The developed Gout Activity Score (GAS) incorporates flare count, sUA, pain VAS, global assessment VAS, joint counts, and tophi burden.
• The GAS demonstrated good criterion validity (correlation with functional disability) and construct validity, with results confirmed in an external validation cohort.

Conclusions:

• A composite Gout Activity Score (GAS) has been successfully developed and validated.
• The GAS shows promise as a tool for measuring gout disease activity.
• Further research is needed to confirm its generalizability, responsiveness, and clinical utility.